Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2023 | Unmet needs in CML: increasing treatment-free remission & accessibility to TKIs

Hagop Kantarjian • 6 Sep 2023
SOHO 2023
Chronic Myeloid Leukemia Leukemia Decitabine Interferon

Hagop Kantarjian, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, describes unmet needs in the field of chronic myeloid leukemia (CML), focusing on the need to increase the rate of treatment-free remission (TFR) as well as to make tyrosine kinase inhibitors (TKIs) more accessible to patients. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Hagop Kantarjian

1:16
Ponatinib for CML and Ph+ ALL: five-year results from the PACE trial
Hagop Kantarjian • 6 Sep 2023
1:39
Cost-benefit considerations for TKI selection in CML
Hagop Kantarjian • 6 Sep 2023
6:23
Venetoclax, CLAD/LDAC and azacitdine in older AML patients
Hagop Kantarjian • 30 Nov 2020
4:44
Ponatinib in chronic-phase CML patients with prior second generation TKI exposure
Hagop Kantarjian • 30 Nov 2020

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals